|Positive WB detected in||Tunicamycin treated HepG2 cells|
|Positive IHC detected in||human liver cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
The immunogen of 21481-1-AP is F9 Fusion Protein expressed in E. coli.
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||F9 fusion protein Ag15723|
|Full Name||coagulation factor IX|
|Calculated molecular weight||461 aa, 52 kDa|
|Observed molecular weight||56 kDa|
|GenBank accession number||BC109215|
|Gene ID (NCBI)||2158|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
The F9 gene encodes coagulation factor IX, which circulates as an inactive zymogen until proteolytic release of its activation peptide allows it to assume the conformation of an active serine protease. Its role in the blood coagulation cascade is to activate factor X (F10) through interactions with calcium, membrane phospholipids, and factor VIII (F8). Factor IX and factor X both consist of 2 polypeptide chains referred to as the L (light) and H (heavy) chains. The H chain bears a structural resemblance to the polypeptide chain of the pancreatic serine protease trypsin (PRSS1). The L chain is covalently linked to the H chain by a single disulfide bond.
Cell Death Dis
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence.
Serum Exosomal Proteins F9 and TSP-1 as Potential Diagnostic Biomarkers for Newly Diagnosed Epilepsy.
EMBO Mol Med
CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.